Loading

Commentary Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.46439/rheumatology.3.018

Dual targeting of plasma cells and B-cells to treat systemic lupus erythematosus

  • 1iCell Gene Therapeutics LLC, Research & Development Division Long Island High Technology Incubator 25 Health Sciences Drive Stony Brook, NY 11790, USA
  • 2Department of Hematology, Peking University Shenzhen Hospital Shenzhen, P.R. China
+ Affiliations - Affiliations

Corresponding Author

Yupo Ma, yupo.ma@icellgene.com

Received Date: February 01, 2022

Accepted Date: March 15, 2022

Abstract

Autoimmune disorders, such as systemic lupus erythematosus, are associated with significant morbidity that is often ultimately refractory to current treatment modalities. To target the role of autoantibodies in disease pathogenesis, biologics have been designed for selective targeting of B-cells. However, results have been disappointing as these modalities are unable to deplete long-lived plasma cells that can continue to produce autoreactive antibodies. To target both B-cells and plasma cells, a BCMA-CD19 compound CAR (cCAR) was tested in a patient with 20-year-history of SLE. Despite cessation of immunosuppressant therapy, cCAR alone led to the normalization of complement and antinuclear antibody levels, indicating an effective response to the therapy. This success of cCAR demonstrates that SLE and other antibody-mediated disorders may benefit from dual resetting of both B-cell and plasma cell populations.

Keywords

Antibody-producing cells, B-cells; Plasma cells, BCMA-CD19 CAR, CD19 cCAR, Autoimmune disorders, Systemic lupus erythematosus (SLE)

Author Information X